{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:38:59Z","timestamp":1793489939037,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005690","name":"Universit\u00e4t des Saarlandes","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005690","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Compounds derived from known drugs are usually brought on the new psychoactive substance (NPS) market without any previous toxicological risk assessment. The European Union Drugs Agency issued an EU early notification for 3,4-methylenedioxyphenmetrazine (MDPM) in 2024. It is structurally related to the stimulants amphetamine, 3,4-methylenedioxymethamphetamine (MDMA), and phenmetrazine and expected to have similar effects. So far, no scientific reports are available describing its toxicokinetic and analytical profile. This study aimed to provide such data to allow a thorough risk assessment and to ease its analytical detectability in forensic and clinical toxicology and doping control. Data reported include the in vitro plasma protein binding, the in vitro half-life and in vitro metabolism of MDPM by human liver microsomes and S9 fraction (pHLS9) and by HepaRG cells. A monooxygenase mapping and the in vitro cytochrome P450 inhibition of MDPM was elucidated. Results showed that HepaRG cells and pHLS9 formed the same MDPM metabolites via demethylenation and <jats:italic>O<\/jats:italic>-methylation and that MDPM has a low plasma protein binding and is a low-turnover drug. Monooxygenase mapping revealed that the demethylenation was exclusively CYP2D6-mediated. MDPM showed strong inhibition of CYP2D6 and moderate inhibition of CYP1A2 and CYP3A4. Polymorphisms or the simultaneous intake of substances that are also CYP2D6 substrates can have a considerable impact on the toxicity of MDPM. Based on in vitro data, the demethylenyl-methyl metabolite of MDPM and the parent compound are recommended as analytical urine screening targets.<\/jats:p>","DOI":"10.1007\/s00204-025-03965-w","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T08:18:14Z","timestamp":1738657094000},"page":"1407-1416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Toxicokinetics and analytical toxicology of the phenmetrazine-derived new psychoactive substance 3,4-methylenedioxyphenmetrazine studied by means of in vitro systems"],"prefix":"10.1007","volume":"99","author":[{"given":"Matthias D.","family":"Kroesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja M.","family":"Gampfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Wagmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4377-6784","authenticated-orcid":false,"given":"Markus R.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"3965_CR1","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/jnc.16149","volume":"168","author":"AS Alberto-Silva","year":"2024","unstructured":"Alberto-Silva AS, Hemmer S, Bock HA et al (2024) Bioisosteric analogs of MDMA: Improving the pharmacological profile? J Neurochem 168:2022\u20132042. https:\/\/doi.org\/10.1111\/jnc.16149","journal-title":"J Neurochem"},{"key":"3965_CR2","first-page":"453","volume":"58","author":"P Baranczewski","year":"2006","unstructured":"Baranczewski P, Stanczak A, Sundberg K et al (2006) Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 58:453\u2013472","journal-title":"Pharmacol Rep"},{"key":"3965_CR3","first-page":"1","volume":"26","author":"N Chauret","year":"1998","unstructured":"Chauret N, Gauthier A, Nicoll-Griffith DA (1998) Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1\u20134","journal-title":"Drug Metab Dispos"},{"key":"3965_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fgene.2012.00235","volume":"3","author":"R de la Torre","year":"2012","unstructured":"de la Torre R, Yubero-Lahoz S, Pardo-Lozano R, Farre M (2012) MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? Front Genet 3:235. https:\/\/doi.org\/10.3389\/fgene.2012.00235","journal-title":"Front Genet"},{"key":"3965_CR5","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1007\/s00216-014-7849-x","volume":"406","author":"J Dinger","year":"2014","unstructured":"Dinger J, Meyer MR, Maurer HH (2014a) Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail. Anal Bioanal Chem 406:4453\u20134464. https:\/\/doi.org\/10.1007\/s00216-014-7849-x","journal-title":"Anal Bioanal Chem"},{"key":"3965_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.toxlet.2014.08.004","volume":"230","author":"J Dinger","year":"2014","unstructured":"Dinger J, Meyer MR, Maurer HH (2014b) Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. Toxicol Lett 230:28\u201335. https:\/\/doi.org\/10.1016\/j.toxlet.2014.08.004","journal-title":"Toxicol Lett"},{"key":"3965_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00204-014-1412-6","volume":"90","author":"J Dinger","year":"2016","unstructured":"Dinger J, Meyer MR, Maurer HH (2016) In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach. Arch Toxicol 90:305\u2013318. https:\/\/doi.org\/10.1007\/s00204-014-1412-6","journal-title":"Arch Toxicol"},{"key":"3965_CR8","unstructured":"EUDA (2023) Synthetic stimulants\u2014the current situation in Europe. European Union Drugs Agency. https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2023\/synthetic-stimulants_en. Accessed 09 July 2024"},{"key":"3965_CR9","unstructured":"EUDA (2024a) Early Warning System on NPS. European Union Drugs Agency. https:\/\/www.euda.europa.eu\/publications\/topic-overviews\/eu-early-warning-system_en. Accessed 17 July 2024"},{"key":"3965_CR10","unstructured":"EUDA (2024b) EU Early Warning System Formal Notification. European Union Drugs Agency. https:\/\/workpage.ews-nfp.bg\/wp-content\/uploads\/2024\/04\/EU-EWS-RCS-FN-2024-0007_34-methylenedioxyphenmetrazine.pdf. Accessed 17 July 2024"},{"key":"3965_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1600-0773.1970.tb00546.x","volume":"28","author":"G Franksson","year":"1970","unstructured":"Franksson G, Anggard E (1970) The plasma protein binding of amphetamine, catecholamines and related compounds. Acta Pharmacol Toxicol 28:209\u2013214. https:\/\/doi.org\/10.1111\/j.1600-0773.1970.tb00546.x","journal-title":"Acta Pharmacol Toxicol"},{"key":"3965_CR12","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00204-020-02726-1","volume":"94","author":"TM Gampfer","year":"2020","unstructured":"Gampfer TM, Wagmann L, Park YM et al (2020) Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4 -fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine. Arch Toxicol 94:2009\u20132025. https:\/\/doi.org\/10.1007\/s00204-020-02726-1","journal-title":"Arch Toxicol"},{"key":"3965_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijpharm.2005.12.022","volume":"311","author":"A Heinze","year":"2006","unstructured":"Heinze A, Holzgrabe U (2006) Determination of the extent of protein binding of antibiotics by means of an automated continuous ultrafiltration method. Int J Pharm 311:108\u2013112. https:\/\/doi.org\/10.1016\/j.ijpharm.2005.12.022","journal-title":"Int J Pharm"},{"key":"3965_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.aca.2015.08.018","volume":"891","author":"AG Helfer","year":"2015","unstructured":"Helfer AG, Michely JA, Weber AA, Meyer MR, Maurer HH (2015) Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening\u2014exemplified for cardiovascular drugs. Anal Chim Acta 891:221\u2013233. https:\/\/doi.org\/10.1016\/j.aca.2015.08.018","journal-title":"Anal Chim Acta"},{"key":"3965_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/0731-7085(95)01504-e","volume":"13","author":"M Laznicek","year":"1995","unstructured":"Laznicek M, Laznickova A (1995) The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs. J Pharm Biomed Anal 13:823\u2013828. https:\/\/doi.org\/10.1016\/0731-7085(95)01504-e","journal-title":"J Pharm Biomed Anal"},{"key":"3965_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/17576180.2024.2365526","volume":"16","author":"C Lier","year":"2024","unstructured":"Lier C, Dejaco A, Kratzer A, Kees MG, Kees F, Dorn C (2024) Free serum concentrations of antibiotics determined by ultrafiltration: extensive evaluation of experimental variables. Bioanalysis 16:747\u2013756. https:\/\/doi.org\/10.1080\/17576180.2024.2365526","journal-title":"Bioanalysis"},{"key":"3965_CR17","doi-asserted-by":"publisher","first-page":"114317","DOI":"10.1016\/j.jpba.2021.114317","volume":"205","author":"M Losacker","year":"2021","unstructured":"Losacker M, Roehrich J, Hess C (2021) Enantioselective determination of plasma protein binding of common amphetamine-type stimulants. J Pharm Biomed Anal 205:114317. https:\/\/doi.org\/10.1016\/j.jpba.2021.114317","journal-title":"J Pharm Biomed Anal"},{"key":"3965_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/dta.1938","volume":"8","author":"M Mardal","year":"2016","unstructured":"Mardal M, Gracia-Lor E, Leibnitz S, Castiglioni S, Meyer MR (2016) Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212\u20132 studied using in vitro tools and LC-HR-MS\/MS. Drug Test Anal 8:1039\u20131048. https:\/\/doi.org\/10.1002\/dta.1938","journal-title":"Drug Test Anal"},{"key":"3965_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.mpmed.2012.04.004","volume":"40","author":"HL McLeod","year":"2012","unstructured":"McLeod HL, He Y (2012) Pharmacokinetics for the prescriber. Medicine 40:357\u2013361. https:\/\/doi.org\/10.1016\/j.mpmed.2012.04.004","journal-title":"Medicine"},{"key":"3965_CR20","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1124\/dmd.108.026203","volume":"37","author":"MR Meyer","year":"2009","unstructured":"Meyer MR, Peters FT, Maurer HH (2009) The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxyethylamphetamine and its single enantiomers. Drug Metab Dispos 37:1152\u20131156. https:\/\/doi.org\/10.1124\/dmd.108.026203","journal-title":"Drug Metab Dispos"},{"key":"3965_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1365-2125.2003.02027.x","volume":"57","author":"M Niemi","year":"2004","unstructured":"Niemi M, Kajosaari LI, Neuvonen M, Backman JT, Neuvonen PJ (2004) The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 57:441\u2013447. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.02027.x","journal-title":"Br J Clin Pharmacol"},{"key":"3965_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jpba.2017.05.028","volume":"143","author":"LHJ Richter","year":"2017","unstructured":"Richter LHJ, Flockerzi V, Maurer HH, Meyer MR (2017) Pooled human liver preparations, HepaRG, or HepG2 cell lines for metabolism studies of new psychoactive substances? A study using MDMA, MDBD, butylone, MDPPP, MDPV, MDPB, 5-MAPB, and 5-API as examples. J Pharm Biomed Anal 143:32\u201342. https:\/\/doi.org\/10.1016\/j.jpba.2017.05.028","journal-title":"J Pharm Biomed Anal"},{"key":"3965_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.toxlet.2019.01.010","volume":"305","author":"LHJ Richter","year":"2019","unstructured":"Richter LHJ, Herrmann J, Andreas A et al (2019) Tools for studying the metabolism of new psychoactive substances for toxicological screening purposes\u2014a comparative study using pooled human liver S9, HepaRG cells, and zebrafish larvae. Toxicol Lett 305:73\u201380. https:\/\/doi.org\/10.1016\/j.toxlet.2019.01.010","journal-title":"Toxicol Lett"},{"key":"3965_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.toxlet.2015.12.001","volume":"243","author":"AE Steuer","year":"2016","unstructured":"Steuer AE, Boxler MI, Stock L, Kraemer T (2016) Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine. Toxicol Lett 243:48\u201355. https:\/\/doi.org\/10.1016\/j.toxlet.2015.12.001","journal-title":"Toxicol Lett"},{"key":"3965_CR25","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.124.001660","author":"E Tseng","year":"2024","unstructured":"Tseng E, Lin J, Strelevitz TJ, DaSilva E, Goosen TC, Obach RS (2024) Projections of drug\u2013drug interactions caused by time-dependent inhibitors of cytochrome P450 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6 using in vitro data in static and dynamic models. Drug Metab Dispos. https:\/\/doi.org\/10.1124\/dmd.124.001660","journal-title":"Drug Metab Dispos"},{"key":"3965_CR26","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/0006-2952(94)90386-7","volume":"47","author":"GT Tucker","year":"1994","unstructured":"Tucker GT, Lennard MS, Ellis SW et al (1994) The demethylenation of methylenedioxymethamphetamine (\u201cecstasy\u201d) by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151\u20131156. https:\/\/doi.org\/10.1016\/0006-2952(94)90386-7","journal-title":"Biochem Pharmacol"},{"key":"3965_CR27","unstructured":"UNODC (2024) Early Warning Advisory on NPS. United Nations Office on Drugs and Crime. https:\/\/www.unodc.org\/LSS\/Page\/NPS. Accessed 09 July 2024"},{"key":"3965_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.toxlet.2016.06.013","volume":"258","author":"L Wagmann","year":"2016","unstructured":"Wagmann L, Meyer MR, Maurer HH (2016) What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? Toxicol Lett 258:55\u201370. https:\/\/doi.org\/10.1016\/j.toxlet.2016.06.013","journal-title":"Toxicol Lett"},{"key":"3965_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fchem.2020.00539","volume":"8","author":"L Wagmann","year":"2020","unstructured":"Wagmann L, Frankenfeld F, Park YM et al (2020) How to study the metabolism of new psychoactive substances for the purpose of toxicological screenings\u2014a follow-up study comparing pooled human liver S9, HepaRG cells, and zebrafish larvae. Front Chem 8:539. https:\/\/doi.org\/10.3389\/fchem.2020.00539","journal-title":"Front Chem"},{"key":"3965_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/8103726","volume":"2017","author":"WR Wan Aasim","year":"2017","unstructured":"Wan Aasim WR, Tan SC, Gan SH (2017) Interspecies in vitro evaluation of stereoselective protein binding for 3,4-methylenedioxymethamphetamine. J Chem 2017:1\u20137. https:\/\/doi.org\/10.1155\/2017\/8103726","journal-title":"J Chem"},{"key":"3965_CR31","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s43440-020-00089-z","volume":"72","author":"J Wojcikowski","year":"2020","unstructured":"Wojcikowski J, Danek PJ, Basinska-Ziobron A, Puklo R, Daniel WA (2020) In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions. Pharmacol Rep 72:612\u2013621. https:\/\/doi.org\/10.1007\/s43440-020-00089-z","journal-title":"Pharmacol Rep"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-025-03965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-025-03965-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-025-03965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T01:36:48Z","timestamp":1743817008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-025-03965-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3965"],"URL":"https:\/\/doi.org\/10.1007\/s00204-025-03965-w","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}